NCT00104338

Brief Summary

The purpose of this study is to assess the safety and effectiveness of a new oral immunosuppressant agent compared to standard care in renal transplant patients diagnosed with BK nephropathy.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Jan 2005

Geographic Reach
1 country

21 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2005

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 24, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 25, 2005

Completed
1.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2006

Completed
Last Updated

June 7, 2012

Status Verified

June 1, 2012

First QC Date

February 24, 2005

Last Update Submit

June 6, 2012

Conditions

Keywords

Investigational TherapiesTreatment EffectivenessTreatment EfficacyImmunosuppressantBK NephropathyPolyomavirus, BKHuman Polyomavirus BKPolyomavirus hominis 1

Outcome Measures

Primary Outcomes (1)

  • Change from baseline in urine BK viral load

Secondary Outcomes (3)

  • Change from baseline in plasma BK viral load

  • Change from baseline in renal function as measured by serum creatinine (SCr) and creatinine clearance (CrCl) at month 6 or at the end of therapy, whichever is earlier

  • Change from baseline in renal histology measured by Drachenberg criteria at month 6 or at the end of therapy, whichever is earlier

Interventions

FK778DRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Renal transplant recipient with newly diagnosed BK nephropathy.

You may not qualify if:

  • Previous treatment for BK nephropathy
  • Organ transplant other than kidney
  • Uncontrolled concomitant infection other than BK nephropathy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (21)

Unknown Facility

Los Angeles, California, 90057, United States

Location

Unknown Facility

Los Angeles, California, 90095, United States

Location

Unknown Facility

San Diego, California, 92123, United States

Location

Unknown Facility

San Francisco, California, 94115, United States

Location

Unknown Facility

San Francisco, California, 94143, United States

Location

Unknown Facility

Denver, Colorado, 80262, United States

Location

Unknown Facility

Washington D.C., District of Columbia, 20010, United States

Location

Unknown Facility

Gainesville, Florida, 32610, United States

Location

Unknown Facility

Jacksonville, Florida, 32216, United States

Location

Unknown Facility

Atlanta, Georgia, 30322, United States

Location

Unknown Facility

Chicago, Illinois, 60612, United States

Location

Unknown Facility

Chicago, Illinois, 60637, United States

Location

Unknown Facility

Wichita, Kansas, 67214, United States

Location

Unknown Facility

Baltimore, Maryland, 21287, United States

Location

Unknown Facility

New Brunswick, New Jersey, 08901, United States

Location

Unknown Facility

Durham, North Carolina, 22710, United States

Location

Unknown Facility

Cincinnati, Ohio, 45267, United States

Location

Unknown Facility

Harrisburg, Pennsylvania, 17104, United States

Location

Unknown Facility

Memphis, Tennessee, 38014, United States

Location

Unknown Facility

Salt Lake City, Utah, 84132, United States

Location

Unknown Facility

Fairfax, Virginia, 22031, United States

Location

Related Publications (1)

  • Wajih Z, Karpe KM, Walters GD. Interventions for BK virus infection in kidney transplant recipients. Cochrane Database Syst Rev. 2024 Oct 9;10(10):CD013344. doi: 10.1002/14651858.CD013344.pub2.

MeSH Terms

Conditions

Kidney Diseases

Interventions

2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide

Condition Hierarchy (Ancestors)

Urologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

February 24, 2005

First Posted

February 25, 2005

Study Start

January 1, 2005

Study Completion

August 1, 2006

Last Updated

June 7, 2012

Record last verified: 2012-06

Locations